

BG SALES-TRADING MORNING DU 21/03/2016

LA SEANCE DE LA VEILLE

INDICES U.S & JAPON			SECTEURS S&P : BEST PERFS			SECTEURS STOXX : BEST PERFS			
Indices	Cloture	Var %	Var 17h30-22H (en %)	S&P	Var %	YTD	STOXX	Var %	YTD
DJ	17602,3	0,7%	-	Banks	2,1	-10,6	Travel & Leisure	1,3	-8,4
NASDAQ	4795,6	0,4%	-	Health Equip.	1,7	-2,1	Auto & Part	1,1	-11
S&P 500	2049,6	0,4%	-	Transportation	1,7	6,4	Technology	1,1	-6,1
NIKKEI	16724,8	-1,2%	-	Semi Conducteurs	1,4	-1,2	Financial Serv.	1	-9,6
			SECTEURS S&P : WORST PERFS.			SECTEURS STOXX : WORST PERFS			
				S&P	Var %	YTD	STOXX	Var %	YTD
				Telecom Op.	-1	13,3	Healthcare	-0,7	-13,3
				Utilities	-0,6	12,4	Oil & Gas	-0,3	3,8
				Food Bev & Tobacco	-0,6	4,8	Real Estate	-0,1	-2,6
				MEDIAS	-0,5	3,2	Telecom	-0,1	-5,2

Valeurs les plus traitées hier vs. Moy. 3M

CAC 40			EURO STOXX 50			STOXX 600		
Stocks*	Last	Var%	Stocks*	Last	Var%	Stock*s	Last	Var%
NOKIA OYJ	5,4	-0,2	SIEMENS AG-REG	92,7	1,5	STEINHOFF INTL	5,6	3,5
ALSTOM	23,7	3,9	MUENCHENER RE	181,4	-1	PROSIEBENSAT.1	45	-3,1
KLEPIERRE	41,7	-0,2	SAFRAN SA	60,8	3,6	INFORMA PLC	685	-0,9
SAFRAN SA	60,8	3,6	BAYER AG-REG	99,3	0,4	SMITHS GROUP PLC	1106	2,8
LAFARGEHOLCIM	39,6	3,1	BASF SE	66,5	2,3	HIKMA PHARMA	1828	-2,8

DEFINITION : * compare les capitaux traités sur une valeur la veille rapportés à la moyenne des capitaux traités ces 3 derniers mois sur la valeur.

TAUX U.S				DEVICES				MAT. PREMIERES			
Taux U.S	Valeur	Var%	Yld	Devises	Valeur	Var%	YTD	Mat. Prem	Valeur	Var%	YTD
U.S 2 ANS	99,8	0%	0,8%	€/€	1,1267	0%	3,3%	BRENT	39,8	-1,9%	11,3%
U.S 10 ANS	97,8	0%	1,9%	€/¥	125,54	0,1%	4%	ONCE OR (\$)	1243,3	-0,9%	17%
VIX Index	14		-2,9%				VSTOXX Index	20,7		-9,2%	

Economic Calendar

CNY - MNI March Business Indicator
 US - Fed's Lacker speaks in Paris at Bank of France
 US - Existing Home Sales Feb. (-2.9% E m/m)
 US - Chicago Fed National Activity index

Dividends Calendar ex-date next day

METSO (MEO1V.HE) 1.05€ (4.74%)

Ex Div today

GIVAUDAN (GIVN.VX) 43.5CHF (2.27%)
 BB BIOTECH (BION.S) 12.25CHF (5.13)
 NOVO NORDISK (NOVOB.CO) 6.4DKK (-1.75%)
 STMICRO (STM.PA) 0.085\$ (1.65%)

Markets Recap (source Street account)

Asian equities are trading mixed on Monday. While the Nikkei is closed for Vernal Equinox Day reports have continued to highlight the debate over the potential for more fiscal support. Mainland China is outperforming with brokerages leading amid reports margin lending rules will be relaxed. The China Development Forum was a weekend focus, though officials didn't really break new ground on policy. PBoC Governor Zhou warned corporate leverage was too high as he and other officials talked up signs of stabilization in economic indicators and capital outflows. Other regions are softer with the ASX weighed down by financials and energy stocks. Australian Prime Minister Turnbull brought forward the Federal Budget announcement by a week, paving the way for an early election.

US equities closed up today. Treasuries were firmer across the curve. The dollar was stronger following its recent decline, gaining against the euro and the yen. Gold was down after yesterday's sizeable rally. Oil was lower, with WTI settling down 1.9%.

It was a very quiet session today with no notable drivers. The market continued its analysis of the week's raft of policy developments. Consumer sentiment slipped to its lowest point since October. At a

conference in Frankfurt, Fed President Bullard suggested that it would be prudent to edge interest rates higher.

ADBE beat on all key metrics. TIF beat with better GM. HOT considers Anbang's proposal superior to MAR's. JPM and BAC boosted their buybacks. CPGX agreed to be acquired by TransCanada. VRX CEO Pearson reassured employees the company would not go bankrupt.

Healthcare led today, but pharma remained a relative underperformer. Banks outperformed. Transportation stocks boosted industrials. Hardware names led the tech sector. Lodging was in focus for consumer discretionary. Industrial metals were mixed. Defensive sectors trailed the market.

Stocks Factor to watch today :

BAYER : Monsanto has approached BAYER to express interest in its crop science unit including a potential acquisition worth more than 30bn\$ (according to people familiar with the matter).

DEUTSCHE BOERSE : some LSE GROUP shareholders are seeking more money in the exchange's planned tie up with DEUTSCHE BOERSE.

TELECOM ITALIA : confirms CEO Patuano is stepping down.

AXA : HENRI de CASTRIES has decided to retire on 1st September 2016. Thomas Duberl to be appointed CEO, Denis Duverne to be appointed Chairman.

UCB : and AMGEN announced positive top line results from phase 3 study evaluating Romozumab in men with Osteoporosis.

CASINO : confirmed its plan to lower its debt after S&P's cut its rating.

TOTAL : Philippe Boisseau, Executive committee member and new energies head, would quit next month to produce solar energy.

FNAC : STEINHOFF offered 975m\$ for DARTY, trumping a competing takeover from FNAC.

GAMELOFT : would appeal the coming days against the AMF's decision to clear Vivendi's hostile takeover bid.

Rating & TP Changes



INDITEX : OUPERFORM vs. MAKERT PERFORM @ *RJM*

AXA : TP raised to 28.5€ vs. 28, Overweight @ *Barclays*



AEGON : TP cut to 6€ vs. 6.1, EQUAL WEIGHT @ *Barclays*

BAYER : TP cut to 111€ vs. 125 @ *JPM*

Technical Analysis

HIGHEST YTD : ADP (ADP.PA), ARCELORMITTAL (ISPA.AS), **BUREAU VERITAS (BVI.PA)**, EIFFAGE (FOUG.PA), **L'OREAL (OREP.PA)**, PUBLICIS GROUP (PUBP.PA), REXEL (RXL.PA), SIEMENS (SIEGn.DE), THALES (TCFP.PA), TOTAL (TOTF.PA)

LOWEST YTD : **ASTRAZENECA (AZN.L)**, BARRY CALLEBAUT (BARN.S), **ROCHE HOLDING (ROG.VX)**

Bryan Garnier ... Today's comment(s)

LafargeHolcim

RATING : BUY

Fair Value CHF50 (+17%)

The press has made different comments last week on a possible issue regarding the price paid by CRH for LH assets. We have contacted both LafargeHolcim and CRH regarding the terms of the agreement of the EUR6.5bn (EV) assets disposal. Actually, both parties have made some comments in their annual reports but both consider it doesn't worth mentioning it at the analyst meeting. This needed a follow-up, although we don't expect any significant consequences from this specific issue. ->**Neutral**.

Atos	RATING : BUY-Top Picks	Fair Value EUR93 (+31%)
-------------	-------------------------------	--------------------------------

The meetings held at our TMT conference were the opportunity for reiterating our Buy (and Top Pick) case on Atos: this is not an organic growth buy, Unify and Equens both create fresh synergy opportunities, and the acquisition strategy - which still has an eye on shareholder value - is well assumed. -> **POSITIVE**

Casino Guichard	RATING : UNDER REVIEW vs. BUY	Fair Value EUR57 (+15%)
------------------------	--------------------------------------	--------------------------------

1/ On December 11th S&P 2015, S&P confirmed the BBB-/Stable outlook credit rating. 2/ On January 2014, Casino increased its disposal programme from EUR2bn to EUR4bn. 2/ On January 15th 2016, S&P took things back and placed Casino Group's BBB- under negative credit watch. 3/ Beginning of January, Casino announced the disposal of the equity stake owned in its listed Thai subsidiary Big C for EUR3.1bn! Ultimately, 4/ On March 21th, S&P downgrades to BB+/stable outlook... There is something wrong in the chain of events. Anyway... maintaining the investment grade was key to us. Even if this downgrade was obviously already priced by the market (see 5Y CDS), the fact remains that the investor base will be largely reduced with this downgrade, while the potential return to the sacrosanct rating should come at a very high price. **Rating under review.**

UCB	RATING : NEUTRAL	Fair Value EUR82 (+18%)
------------	-------------------------	--------------------------------

UCB and Amgen reported positive phase III results for Romosozumab in men suffering from osteoporosis (BRIDGE trial) that should support filing in Japan. While the trial met its primary endpoint of bone mineral density at the lumbar spine vs. placebo at 12 months. We would underline that cardiovascular SAEs was 4.6% (n=8) in the romosozumab group compared to 2.5% in the placebo group (n=2) which might trigger an increased scrutiny by the regulator and potentially additional trial to assess CV issues. **NEUTRAL**
